Triclosan
CAS 3380-34-5
Triclosan (CAS 3380-34-5) is a Phase 4 pharmaceutical compound with 9 bioactivity targets and 1,767 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | MIC | 76.97677181208054 ug.mL-1 | 149 | - |
| - | IC50 | 7006.051219512195 nM | 82 | - |
| - | AC50 | 26079.720253164556 nM | 76 | - |
| - | Potency | 27398.07441860465 nM | 37 | - |
| - | Ki | 92.3631984 nM | 25 | - |
| - | MIC | 19728 nM | 25 | - |
| - | EC50 | 13719.23076923077 nM | 13 | - |
| - | IC50 | 0.014333333333333332 ug.mL-1 | 3 | - |
| - | EC50 | 6.050000000000001 ug.mL-1 | 2 | - |
| Enoyl-[acyl-carrier-protein] reductase [NADH] Enzyme |
Ki | 6.7 | - | Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) |
| Carbonyl reductase [NADPH] 1 Enzyme |
Ki | 7.22 | - | Homo sapiens |
| Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI Enzyme |
IC50 | 7.15 | - | Staphylococcus aureus (strain MRSA252) |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI Enzyme |
IC50 | 6.37 | - | Escherichia coli (strain K12) |
| Enoyl-acyl-carrier protein reductase Enzyme |
Ki | 10.28 | - | Plasmodium falciparum |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI Enzyme |
IC50 | 6.3 | - | Bacillus subtilis (strain 168) |
| Enoyl-acyl carrier reductase; Enoyl-acyl carrier reductase ENR Enzyme |
IC50 | 7.82 | - | Toxoplasma gondii |
| Enoyl-ACP reductase Enzyme |
IC50 | 6.7 | - | Plasmodium falciparum |
| Enoyl-[acyl-carrier-protein] reductase [NADPH] Enzyme |
IC50 | 7.23 | - | Staphylococcus aureus |
| Enoyl-[acyl-carrier-protein] reductase [NADH] Enzyme |
IC50 | 5.89 | - | Francisella tularensis subsp. tularensis (strain SCHU S4 / Schu 4) |
| Enoyl-[acyl-carrier-protein] reductase [NADH] Enzyme |
Ki | 6.7 | - | Mycobacterium tuberculosis |
| 78 kDa glucose-regulated protein Unclassified |
IC50 | 4 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Toxic epidermal necrolysis | 38 | 173.118 | 10044223 |
| Drug hypersensitivity | 27 | 56.673 | 10013700 |
| Product use in unapproved indication | 23 | 49.384 | 10076476 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| TRICLOSAN | 10795 | SU | MTHSPL |
| triclosan | 10795 | IN | RXNORM |
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Hypersensitivity | triclosan | LLT | C0020517 |
| Hypersensitivity | triclosan | PT | C0020517 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Triclosan used for in pharmaceutical contexts?
Triclosan (CAS 3380-34-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Triclosan?
Triclosan has 1,767 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Toxic epidermal necrolysis, Drug hypersensitivity, Product use in unapproved indication, Abdominal discomfort, Abdominal distension. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Triclosan also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Triclosan with EU status "restricted".
What clinical phase is Triclosan in?
Triclosan is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Triclosan?
Triclosan has 21 bioactivity rows in this page query. Rendered target entries include Enoyl-[acyl-carrier-protein] reductase [NADH], Carbonyl reductase [NADPH] 1, Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI, Enoyl-[acyl-carrier-protein] reductase [NADH] FabI, Enoyl-acyl-carrier protein reductase.